Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 1 SUPPL., 2008, Pages

  Sinkovics, Joseph G ^a,c   Horvath, Joseph C ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b HEMISPHERX BIOPHARMA INC   (United States)

^c ST JOSEPH HOSPITAL   (United States)

Author keywords

Genetically engineered oncolytic viruses; Human cancer immunity; Interaction of resident viral flora with the oncolytic virus; Naturally oncolytic viruses; Oncosuppressive bacteriophages; Viral oncolysates

Indexed keywords

ADVEXIN; ALPHA2B INTERFERON; BCG VACCINE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; E1A PROTEIN; ETANERCEPT; FLUOROURACIL; FOLINIC ACID; G 207; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES VIRUS ONCOLYSATE; INFLUENZA VACCINE; INFLUENZA VIRUS ONCOLYSATE; INTERLEUKIN 2; MELANOMA VACCINIA VIRUS ONCOLYSATE; MEVINOLIN; MUMPS VACCINE; NEWCASTLE DISEASE VACCINE; ONCOLYTIC VIRUS; ONCOVEX; ONYX 015; OXALIPLATIN; PARVOVIRUS ONCOLYSATE; POLIOVIRUS RHINOVIRUS ONCOLYSATE; PV 701; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; REOLYSIN; REOVIRUS ONCOLYSATE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS ONCOLYSATE; VESICULAR STOMATITIS VIRUS ONCOLYSATE; VIRUS ONCOLYSATE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; BACTERIOPHAGE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER RELAPSE; COLON; DRUG EFFICACY; DRUG MEGADOSE; GENE THERAPY; GENETIC ENGINEERING AND GENE TECHNOLOGY; HISTORY OF MEDICINE; HUMAN; INFLUENZA VIRUS A; LOW DRUG DOSE; LYMPHOCYTE; METASTASIS; NEOPLASM; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARAMYXOVIRUS; PARVOVIRUS; REOVIRUS; REPEATED DRUG DOSE; REVIEW; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR XENOGRAFT; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS STRAIN;

ANIMALS; APOPTOSIS; BACTERIOPHAGES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 59849122602     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0047-9     Document Type: Review

References (479)

1. Ackerman W. W. and Kurtz H. (1952): A new host-virus system. Proc. Soc. Exp. Biol., 81, 421-423.
2. Aghi M. S., Rabkin S. and Martuza R. L. (2007): Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering thrombospondin-derived peptid. Cancer Res., 67, 440-444.
3. Aghi M., Visted T., Depinho R. A. and Chiocca E. A. (2008): Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene, 27, 4249-4254.
4. Ajayi B. B., Rabo J. S. and Baba S. S. (2006): Rabies in apparently healthy dogs: histological and immunohistological studies. Niger Postgrad. Med., 13, 128-134.
5. Alain T., Kim M., Johnston R. N., Urbanski S., Kossakowska A. E., Forsyth P. A. and Lee P. W. (2006): The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br. J. Cancer, 95, 1020-1027.
6. Alemany R. (2007): Cancer selective adenoviruses. Mol. Aspects Med., 28, 42-58.
7. Allen C., Vongpunsawad S., Nakamura T., James C. D., Schroeder M, Cattaneo R., Guanni C., Kempinski J., Peng K., Goble J. J., Uhm J. H., Russell S. J. and Galanis E. (2006): Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res., 66, 11840-11850.
8. Alonso M. M., Cascallo M., Gomez-Manzano C., Jiang H., Bekele R. N., Perez-Gimenez A., Lang F. F., Piao Y., Alemany R. and Fueyo J. (2007): ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res., 67, 8255-8263.
9. Alonso M. M., Gomez-Manzano C., Juang H., Bekele N. B., Piao Y., Yung W. K., Aleman R. and Fueyo J. (2007): Combination of oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced antiglioma effect in vivo. Cancer Gene Ther., 14, 756-761.
10. Anonymous (2007): INGN 201: Ad-p53. Ad5CMV-p53, adenoviral p53, p53 gene therapy - Introgen, RPR/INGN 201. Drugs R D, 8, 176-187.
11. Aoki K., Oh-hira M., Hoshino M. and Kawakita M. (1994): Isolation and characterization of a novel mutant mouse cell line resistant to Newcastle disease virus: constitutive interferon production and enhanced interferon sensitivity. Arch. Virol., 139, 337-350.
12. Apostolidis L., Schirrmacher V. and Fournier P. (2007): Host-mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int. J. Oncol., 31, 1009-1019.
13. Arakawa S. Jr., Hamami G., Umezu K., Kamidono S., Ishigami J. and Arakawa S. (1987): Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report of two cases. J. Cancer Res. Clin. Oncol., 13, 95-98.
14. Arlen P. M., Gulley J. L., Parker C., Skarupa L., Pazdur M., Panicali D., Beetham P., Tsang K.Y., Grosenbach D. W., Feldman J., Steinberg S. M., Jones E. Chen C., Marte J., Schlom J. and Dahut W. (2006): A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res., 12, 1260-1269.
15. Arrington A. S., Moore M. S. and Butel J. S. (2004): SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus. Oncogene, 23, 2231-2235.
16. Asada T. (1974): Treatment of human cancers with mumps virus. Cancer, 34, 1907-1928.
17. Au G. G., Lincz L. F., Enno A. and Shafren D. R. (2007): Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. Br. J. Haematol., 137, 133-141.
18. Balachandran S. and Barber G. N. (2007): PKR in innate immunity, cancer, and viral oncolysis. Methods Mol. Biol., 383, 277-301.
19. Ballagi-Pordany A., Wehmann E., Herczeg J., Belak S. and Lomniczi B. (1996): Identification and grouping of Newcastle disease virus strains by restriction site analysis of a region from F gene. Arch. Virol., 141, 243-261.
20. Banki K., Maceda J., Hurley E., Ablonczy E., Mattson D. H., Szegedi L., Hung C. and Perl A. (1992): Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: a possible autoantigen for HTLV-1 gag-reactive autoantibodies. Proc. Natl. Acad. Sci. USA, 89, 1939-1943.
21. Bantel-Schaal U. (1995): Growth properties of a human melanoma cell line are altered by adeno-associated parvovirus type 2. Int. J. Cancer, 60, 269-274.
22. Barber G. N. (2005): VSV tumor-selective replication and protein translation. Oncogene, 24, 7710-7719.
23. Barrett J. W., Sypula J., Wang F., Alston L. R., Shao Z., Gao X., Irvine T. S. and McFadden G. (2007): M135R is a novel cell surface virulence factor of myxoma virus. J. Virol., 81, 106-114.
24. Bartlett D. L. (2001): Vaccinia virus. In Hernáiz Driever P. and Rabkin S. D. (eds.): Replication Competent Viruses for Cancer Therapy. Karger, Basel-Paris-London, 130-159.
25. Basombrio M. A. (1980): Immunity to Friend virus complex: analysis of protection with a sarcoma virus pseudotype. Arch. Geschwultsforsch., 50, 309-316.
26. Basombrio M. A., Mayer A. M. and Pasqualini C. D. (1977): Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis. Cancer Res., 37, 1768-1776.
27. Bateman A. R., Harrington K. J., Kottke T., Ahmed A., Melcher A. A., Gough M. J., Linardakis E., Riddle D., Dietz A., Lohse C. M., Strome S. T., Peterson T., Simari R. and Vile R. G. (2002): Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res., 62, 6566-6578.
28. Batliwalla F. M., Bateman B. A., Serrano D., Murray D., Macphail S. Maino V. C, Ansel J. C., Gregersen P. K. and Armstrong C. A. (1998): A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med., 4, 783-794.
29. Berencsi K., Beladi I. and Juhasz A. (1974): Interferon production and immunosuppression in NDV infected hamsters. Z. Immunitätsforsch. Exp. Klin. Immunol., 147, 441-448.
30. Bergman I., Griffin J. A., Gao Y. and Whitaker-Dowling P. (2007): Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer, 121, 425-430.
31. Berthier-Vergnes O., Portoukalian J., Lefthériotis E. and Doré J. F. (1994): Induction of IgG antibodies directed to a Mr 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res., 54, 2433-2439.
32. Bhat R. Eissmann P. Endt J. Hoffmann S. and Watzl C. (2006): Fine-tuning of immune response by SLAM-related receptors. J. Leukoc. Biol., 79, 417-424.
33. Bian H., Fournier P., Moormann R., Peeters R. B. and Schirrmacher V. (2005): Selective gene transfer to tumor cells by recombinant Newcastle disease virus via a bispecific fusion protein. Int. J. Oncol., 26, 431-439.
34. Bilsland A. E., Merron A., Vassaux G. and Keith W. N. (2007): Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res., 67, 1299-1307.
35. Blazsek A., Sillo P., Ishii N., Gergely P. G. Jr., Poor G., Preisz K., Hashimoto T., Medvecz M. and Kárpáti S. (2008): Searching for foreign antigens as possible triggering factors of autoimmunity: Torque Teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid. Exp. Dermatol., 17, 446-454.
36. Bluming A. Z. and Ziegler J. I. (1971): Regression of Burkitt's lymphoma in association with measles infection. Lancet, 2, 105-106.
37. Boone C. W., Orme T. W., Blackman K. and Gillette R. (1973): Preparation of membrane fractions with enhanced tumor-transplantation antigen activity from tumor cells infected with influenza virus. J. Natl. Cancer Inst., 51, 1141-1144.
38. Bos R., van Duikeren S., van Hall T., Lauwen M. M., Parrington M., Berinstein N. L., McNeil B., Melief C. J., Verbeek J. S., van der Burg S. H. and Offringa R. (2007): Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J. Immunol., 179, 6115-6122.
39. Bostwick D. G., Null W. E., Holmes D., Weber F., Barchas J. D. and Bensch K. G. (1987): Expression of opioid peptides in tumors. N. Engl. J. Med., 317, 1439-1443.
40. Breckpot K., Aerts J. L. and Thielmans K. (2007): Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther., 14, 847-862.
41. Breitbach C. J., Paterson J. M., Lemay C. G., Falls T. J., McGuire A., Parato K. A., Stojdl D. F., Daneshmand M., Speth K., Kirn D., McCart J. A., Atkins H. and Bell J. C. (2007): Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther., 15, 1686-1693.
42. Brentano L., Lazzarin S., Bassi S. S., Klein T. A. and Schat E. A. (2005): Detection of chicken anemia virus in the gonads and in the progeny of broiler breeder hens with high neutralizing antibody titers. Vet. Microbiol., 105, 65-72.
43. Campbell S. A., Mulvey M., Mohr I. and Gromeier M. (2007): Attenuation of herpes simplex virus with IRES acting genetic elements. J. Virol., 81, 791-799.
44. Carr D. J., Rogers T. J. and Weber R. J. (1996): The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc. Soc. Exp. Biol. Med., 213, 248-257.
45. Cascallo M., Alonso M. M., Rojas J. J., Perez-Gimenez A., Fueyo J. and Alemany R. (2007): Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther., 15, 1607-1615.
46. Cassel W. A. and Garrett R. E. (1965): Newcastle disease virus as an antineoplastic agent. Cancer, 18, 863-868.
47. Cassel W. A. and Garrett R. E. (1967): Relationship between viral neurotropism and oncolysis. I. Study of vaccinia virus. Cancer, 20, 433-439.
48. Cassel W. A. and Garrett R. E. (1967): Relationship between viral neurotropism and oncolysis. II. Study of influenza virus. Cancer, 20, 440-444.
49. Cassel W. A. and Murray D. R. (1992): A ten-year follow-up of stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother., 9, 169-171.
50. Cassel W. A., Murray D. R. and Olkowski Z. I. (2005): Newcastle disease virus oncolysate in the management of stage III malignant melanoma. In Sinkovics J. G. and Horvath J. C. (eds.): Viral Therapy of Human Cancers. Marcel Dekker, New York, 677-689.
51. Césaire R., Olière S., Sharif-Askari E., Loignon M., Lézin A., Olindo S, Panelatti G., Kazanji M., Aloyz R., Panasci L., Bell J. C. and J. Hiscott J. (2006): Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene, 25, 349-358.
52. rd, Guo Z. S. and Bartlett D. L. (2008): Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with yeast cytosine deaminase gene. Cancer Gene Ther., 15, 115-125.
53. Chan J. C., Mohr M. D., Knesek J. E., Bowen J. M. and East J. L. (1981): Inhibition of the release of virion-associated murine leukemia virus genomic RNA by vesicular stomatitis virus. Intervirology, 16, 191-200.
54. Chany-Fournier F., Chany C. and Lafay F. (1977): Mechanism of polykaryocyte induction by vesicular stomatitis virus in rat XC cells. J. Gen. Virol., 34, 305-314.
55. Chiocca E. A. (2008): The host response to cancer virotherapy. Curr. Opion. Mol. Ther., 10, 38-45.
56. Cho K., Lee Y. K. and Greenhalgh D. G. (2008): Endogenous retroviruses in systemic response to stress signals. Shock, 30, 105-116.
57. Chua K. B., Crameri G., Hyatt A., Yu M., Tompang M. R., Rosli J., McEachern J., Crameri S., Kumarasamy V., Eaton B. T. and Wang L.-F. (2007): A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc. Natl. Acad. Sci. USA, 104, 11424-11429.
58. Clarke P., Debiasi R. L., Goody R., Hoyt C. C., Richardson-Burns S. and Tyler K. L. (2005): Mechanisms of reovirus-induced cell death and tissue injury: role of apoptosis and virus-induced perturbation of host-cell signaling and transcription factor activation. Viral Immunol., 18, 89-115.
59. Corbin A. and Sitbon M. (1993): Protection against retroviral disease after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses. J. Virol., 67, 5146-5152.
60. Cornelis J. J., Salomé N., Dinsart C. and Rommelaere J. (2004): Vectors based on autonomous parvoviruses: novel tools to treat cancer. J. Gene Med., suppl. 1, S193-202.
61. Courrèges M. C., Benecia F., Conejo-García J. R., Zhang L. and Coukos G. (2006): Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer Gene Ther., 13, 182-193.
62. Crouch N. A. and Mitchell R. L. (1979): Replication of vesicular stomatitis virus facilitated by Shope fibroma virus in vivo. Infect. Immunol., 25, 213-219.
63. Csatary L. K., Eckhardt S., Bukosza I., Czegledi F., Fenyvesi C., Gergely P., Bodey B. and Csatary C. M. (1993): Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev., 17, 619-627.
64. Czeglédi A., Újvári D., Somogyi E., Wehmann E., Werner O. and Lomniczi B. (2006): Third genome size category of avian paramyxovirus serotype 1 (Newcastle disease virus) and evolutionafry implications. Virus Res., 120, 36-48.
65. Czeglédi A., Wehmann E. and Lomniczi B. (2003): On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts'33. Avian Pathol., 32, 271-276.
66. Dabrowska K., Opolski A., Wietrzyk J., Switala-Jelen K., Boratynski J., Nasulewicz A., Lipinska L., Chybicka A., Kujawa M., Zabel M., Dolinska-Krajewska B., Piasecki E., Weber-Dabrowska B., Rybka J., Salwa J., Wojdat E., Nowaczyk M. and Gorski A. (2004): Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway. Acta Virol., 48, 241-248.
67. Dabrowska K., Opolski A., Wietrzyk J., Switala-Jelen K., Godlewska J., Boratynski J., Syper D., Weber-Dabrowska B. and Gorski A. (2004): Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumor models. Anticancer Res., 24, 3991-3996.
68. Danen-van Oorschot A. A., Voskamp P., Seelen M. C., van Miltenburg M. H., Bolk M. W., Tait S. W., Boesen-de Cock J. G., Rohn J. L., Borst J. and Noteborn M. H. (2004): Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor preferential cell killing. Cell Death Differ., 11, 564-573.
69. De Filippo K., Henderson R.B., Laschinger M. and Hogg N. (2008): Neutrophil chemokines KC and macrophage--inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol., 180, 4308-4315.
70. De Laurenzi V., Melingo G., Knight R.A., Pierotti R. A. and Cohen P. (1993): Modulation of POMC expression in human neuroectodermal cells. Biochem. Biophys. Res. Commun., 197, 1402-1409.
71. de Leeuw O. and Peeters B. (1999): Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. Gen. Virol., 80, 131-136.
72. Deng X., He G., Levine A. Y., Cao Y. and Mullins C. (2007): Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int. J. Cancer, 122, 209-218.
73. De Pace N. G. (1912): Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica. Ginecologia, 9, 82-88.
74. Dermer G. (1993): The Immortal Cell. Why Cancer Research Fails. Avery Publisher, Garden City Park, New York, 1-224.
75. Dieli F., Abrignani S., Lio D. and Salerno A. (1988): Role of macrophages in bypassing the inhibitory activity of Newcastle disease virus on the T-suppressor-cell circuit which regulates contact sensitivity to picryl chloride. Cell. Immunol., 111, 332-340.
76. Diniz-Mendes L., Paula V. S., Luz S. L. and Niel C. (2008): High prevalence of human Torque teno virus in streams crossing the city of Manaus, Brazilian Amazon. J. Appl. Microbiol., 105, 51-58.
77. Di Piazza M., Mader C., Geletneky K., Herrero Y., Calle M., Weber E., Schlehofer J., Deleu L. and Rommelaere J. (2007): Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol., 81, 4186-4198.
78. DiStefano A. D. and Buzdar A. U. (1979): Viral-induced remission in chronic lymphocytic leukemia? Arch. Int. Med., 139, 946.
79. Dock G. (1904): The influence of complicating diseases upon leukemia. Am. J. Med. Sci., 127, 563-592.
80. Dong B., Kim S., Hong S., Das Gupta J., Malathi K., Klein E. A., Ganem D., Derisi J. L., Chow S. A. and Silverman R. H. (2007): An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. USA, 104, 1655-1660.
81. Doré J. F., Portukalian J., Berthier-Vergnesm O., Jacubovich R., Genève J., Bailly M., Lefthériotis E., Weissbrod A. and Mayer M. (1990): Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus. Bull. Cancer, 77, 881-889.
82. Dunn A. J. and Vickers S. L. (1994): Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res., 645, 103-112.
83. Durso R. J., Andjelic S., Gardner J. P., Marglitich D. J., Donovan G. P., Arrigale R. R., Wang X., Maughan M. F., Talarico T. L., Olmsted R. A., Heston W. D., Maddon P. J. and Olson W. C. (2007): A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res., 13, 3999-4008.
84. Eaton M. D., Levinthal J. D. and Scala A. R. (1967): Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma. J. Natl. Cancer Inst., 39, 1089-1097.
85. Ebert O., Shinozaki K., Huang T. G., Savontaus M. J., García-Sastre A. and Woo S. L. (2003): Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res., 63, 3605-3611.
86. Editorial (1977): Suppressive effect of Newcastle disease virus on the primary and secondary immune responses of hamsters. Acta Virol., 21, 296-300.
87. Efferson C. L., Tsuda N., Kawano K., Nistal-Villán E., Sellapan S., Yu D., Murray J. L., García-Sastre A. and Ioannides C. G. (2006): Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J. Virol., 80, 383-394.
88. Elango N. (1989): The mumps virus nucleocapsid mRNA sequence and homology among the Paramyxoviridae proteins. Virus Res., 12, 77-86.
89. Elankumaran S., Rockermann D. and Samal S. K. (2006): Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol., 80, 7522-7534.
90. Ember I., Szöllõsi J., Thomázy V., Arany I., Rády P. and Kertai P. (1982): A rapid method of following the spontaneous regression of experimental leukemias. Experientia, 38, 1234-1235.
91. Eriksson F., Culp W. D., Massey R., Egevad L., Garland D., Persson M. A. and Pisa P. (2007): Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol. Immunother., 56, 677-687.
92. Errington F., Bateman A., Kottke T., Thompson J., Harrington K., Merrick A., Hatfield P., Selby P., Vile R. and Melcher A. (2006): Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin. Cancer Res., 12, 1333-1341.
93. Everall J. D., O'Doherty C. L., Wand J. and Dowd P. M. (1975): Treatment of primary melanoma by intralesional vaccinia before excision. Lancet, 2, 583-586.
94. Everson R. G., Gromeier M. and Sampson J. H. (2007): Viruses in the treatment of malignant glioma. Expert Rev. Neurother., 7, 3212-324.
95. Fábián Z., Csatary C. M., Szeberényi J. and Csatary L. K. (2007): p53-Independent endoplasmic reticulum stress--mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J. Virol., 81, 2817-2830.
96. Fábián Z., Törõcsík B., Kiss K., Csatary L., Bodey B., Tigyi J., Csatary C. and Szeberényi J. (2001): Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in P12 rat phaeochromocytoma cells. Anticancer Res., 21, 125-136.
97. Fadly A. and Garcia M. C. (2006): Detection of reticuloendotheliosis virus in live virus vaccines of poultry. Dev. Biol., 126, 301-305.
98. Fan H. (2007): A new human retrovirus associated with prostate cancer. Proc. Natl. Acad. Sci. USA, 104, 1449-1450.
99. Farkas T., Drén C., Németh I., Dobos-Kovács M., Povazsán J. and Sághy E. (1992): Isolation of chicken anaemia virus from broiler chickens. Acta Vet. Hung., 40, 207-223.
100. Farnsworth A., Wisner T.W., Webb M., Roller R., Cohen G., Eisenberg R. and Johnson D. C. (2007): Herpes simplex virus glycoproteins gB and gH function in fusion between the virion envelope and the outer nuclear membrane. Proc. Natl. Acad. Sci. USA, 104, 10187-10192.
101. Feng H., Shuda M., Chang Y. and Moore P. S. (2008): Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 319, 1096-1100.
102. Fiola C., Peeters B., Fournier P., Arnold A., Bucur M. and Schirrmacher V. (2006): Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer, 119, 328-338.
103. Flotte T. R. (2007): Gene therapy: the first two decades and the current state-of the-art. J. Cell. Physiol., 213, 301-305.
104. Freedman R. S., Bowen J. M., Herson H., Wharton J. T., Edwards C. L. and Rutledge F. (1983): Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. Obstet. Gynecol., 62, 707-714.
105. Freedman R. S., Edwards C. L., Bowen J. M., Lotzova E., Katz R., Lewis E., Atkinson A. and Carsetti R. (1988): Viral oncolysates in patients with advanced ovarian cancers. Gynecol. Oncol., 29, 337-347.
106. Freedman R. S., Edwards C. L., Bowen J. M., Tomasovic B., Patenia R. and Scott W. (1993): Virustherapy for gynecological tumors. In Second European Congress Gynecologic Endoscopy New Techniques. Monduzzi Editore, 35-42.
107. Freeman A. I., Gomori J. M., Linetsky E., Zakay-Rones Z., Panet A., Libson E., Irving C. S., Galun E. and Siegal T. (2004): Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme. American Society of Clinical Oncology, 40th Annual Meeting, New Orleans, June 5-8. Proceedings, 23, 110. Abstract #1515.
108. Freeman A. I., Zakay-Rones Z., Gomori J. M., Linedtky E., Rasooly L., Greenbaum E., Rozenmann-Yair S., Panet A., Libson E., Irving C. S., Galun E. and Siegal T. (2006): Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther., 13, 221-228.
109. Fu X., Nakamori M., Tao T., Amato R. and Zhang X. (2007): Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int. J. Oncol., 30, 1561-1567.
110. Fu X., Tao L., Cai R., Prigge J. and Zhang X. (2006): A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene as a potent oncolytic virus. Mol. Ther., 13, 882-890.
111. Fu X., Tao L. and Zhang X. (2007): An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther., 14, 480-487.
112. Fueyo J., Alemany R., Gomez-Manzano C., Fuller G. N., Khan A., Conrad C. A., Liu T. J., Jiang H., Lamoine M.G., Suzuki K., Sawaya R., Curiel D. T., Yung W. K. and Lang F. F. (2003): Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst., 95, 652-660.
113. Fugier-Vivier I., Servet-Delprat C., Rivailler P., Rissoan M. C., Lin Y. J. and Rabourdin-Combe C. (1997): Measles virus suppresses cell-mediated immunity by interfering with the survival and function of dendritic and T cells. J. Exp. Med., 186, 813-823.
114. Fujiwara T., Urata Y. and Tanaka N. (2007): Telomerase--specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr. Cancer Drug Targets, 7, 191-201.
115. Fulci G., Dmitrieva N., Gianni D., Fontana E. J., Pan X., Lu Y., Kaufman C. S., Kaur B., Lawler S. E., Lee R. J., Marsh C. B., Brat D. J., van Rooijen N., Rachamimov A. S., Hochberg F. H., Weissleder R., Martuza R. L. and Chiocca E. A. (2007): Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res., 67, 9398-9406.
116. Gabaglia C. R., de Durana Y. D., Graham F. L., Gauldie J., Sercarz E. E. and Braciak T. A. (2007): Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res., 67, 2290-2297.
117. Gabrilove J. L., Anderson P. J. and Halmi N. S. (1986): Pituitary pro-opiomelanocortin-cell carcinoma occurring in conjunction with a glioblastoma in a patient with Cushing's disease and subsequent Nelson's syndrome. Clin. Endocrinol., 25, 117-126.
118. Gallyas É., Seprényi Gy., Sonkoly E., Mándi Y., Kemény L. and Megyeri K. (2006): Vesicular stomatitis virus induces apoptosis in the Wong-Kilbourne derivative of the Chang conjunctival cell line. Graefe's Arch. Clin. Exp. Ophthalmol., 244, 717-724.
119. Gao J. Q., Kanagawa N. D., Xu D. H., Han M., Sugita T., Hatanaka Y., Tani Y., Mizuguchi H., Tsutsumi Y., Mayumi T., Okada N. and Nakagawa S. (2008): Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin-12, elicits notably enhances anti-tumor responses. Cancer Immunol. Immunother., 57, 1657-1664..
120. Gao Y., Whitaker-Dowling P., Watkins S. C., Griffin J. A. and Bergman I. (2006): Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J. Virol., 80, 8603-8612.
121. Gergely P. Jr., Perl A. and Poór G. (2006): Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases? Autoimmun. Rev., 6, 5-9.
122. Gergely P. G. Jr., Pullmann R., Stancato C., Otvos L. Jr., Koncz A., Blazsek A., Poor G., Brown K. E., Phillips P. E. and Perl A. (2005): Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin. Immunol., 116, 124-134.
123. Giese N. A., Raykov Z. L., deMartino L., Vecchi A., Sozzan S., Dinsart C., Cornelis J. J. and Rommelaere J. (2002): Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther., 9, 432-442.
124. Gil Z., Rein A., Brader P., Li S., Shah J. P., Fong Y. and Wong R. J. (2007): Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin. Cancer Res., 13, 6479-6485.
125. th International Conference on Oncolytic Viruses as Cancer Therapeutics. Mayo Clinic College of Medicine, Rochester, USA, Poster 10.
126. Gomella L. G., Mastrangelo M. J., McCue P. A., Maguire H. C., Mulholland J. R. and Lattime E. C. (2001): Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol., 166, 1291-1295.
127. Gomez-Manzano C., Alonso M. M., Yung W. K., McCormick F., Curiel D. T., Lang F. F., Jiang H., Bekele B. N., Zhou X., Alemany R. and Fueyo J. (2006): Delta--24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin. Cancer Res., 12, 556-562.
128. Goncalves J. C. (1966): Malignant change in smallpox vaccination scars. Arch. Dermatol., 93, 229-230.
129. Gopalan B., Shanker M., Scott A., Branch C. D., Chada S. and Ramesh R. (2008): MDA-7/IL-24, a novel tumor suppressor/ cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA--7/IL-24 degradation enhances the antitumor activity. Cancer Gene Ther., 15, 1-8.
130. Górski A., Dabrowska K., Switala-Jeleñ K., Nowaczyk M., Weber-Dabrowska B., Boratynski J., Wietrzyk J. and Opolski A. (2003): New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol., 2, 1-10.
131. Górski A. and Weber-Dabrowska B. (2005): The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol. Life Sci., 62, 511-519.
132. Gönczöl E., Boldogh I. and Váczi L. (1980): Vesicular stomatitis virus pseudotypes produced by cells abortively infected or transfomed by human cytomegalovirus. Arch. Virol., 66, 255-260.
133. Graat H. C., Carette J. E., Schagen F. H., Vassilev L. T., Gerritsen W. R., Kaspers G. J., Wuisman P. I. and van Beusechem V. W. (2007): Enhanced tumor cell kill by combined treatment with a small molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol. Cancer Ther., 6, 1552-1561.
134. Greenberger J. S. and Aaronson S. A. (1973): In vivo inoculation of RNA C-type viruses inducing regression of experimental solid tumors. J. Natl. Cancer Inst., 51, 1933-1938.
135. Greentree L. B. (1983): Hodgkin's disease: therapeutic role of measles vaccine. Am. J. Med., 75, 928.
136. Greiner S., Humrich J. Y., Thuman P., Sauter B., Schuler G. and Jenne L. (2006): The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin. Exp. Immunol., 146, 344-353
137. Guo Z. S., Thorne S. H. and Bartlett D. L. (2008): Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta, 1785, 217-231.
138. Gupta S., Plattner R., Der C. J. and Stanbridge E. J. (2000): Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of fibrosarcoma cells: evidence for a potential novel pathway. Mol. Cell Biol., 20, 9294-9304.
139. Haas C., Erte C., Gerhards R. and Schirrmacher V. (1998): Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle disease virus. Int. J. Oncol., 13, 1105-1115.
140. Hafez M. M., Shaarawy S. M., Hassan A. A., Salim R. F., Abd El Salam F. M. and. Ali A. E. (2007): Prevalence of transfusion-transmitted virus (TTV) genotypes among HCC (Egyptian hepatocellular carcinoma) patients in Qaluobia governorate. Virol. J., 4, 135.
141. Hagglund R. and Roizman B. (2004): Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1. J. Virol., 78, 2169-2178.
142. Hakim S. T., Alsayari M., McLean D. C., Saleem S., Addanki K. C., Aggarwal M., Mahalingam K. and Bagasra O. (2008): A large number of human microRNAs target lentiviruses, retroviruses, and endogenous retroviruses. Biochem. Biophys. Res. Commun., 369, 357-362.
143. Hallenbeck P. L., Burroughs K. D., Hales L. M., Neefe J. R., Reddy P. S. and Rudin C. M. (2007): A phase I trial of Seneca Valley Virus (NXT-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients having solid tumors with neuroendocrine features. In The 4th International Conference on Oncolytic Viruses as Cancer Therapeutics. Collection of Abstracts, Mayo Clinic College of Medicine, Rochester, USA. Abstract Book, p. 20.
144. Hammon W. M., Yohn D. S., Casto B. C. and Atchison R. W. (1963): Oncolytic potentials of nonhuman viruses for human cancer. I. Effects of twenty-four viruses on human cancer cell lines. J. Natl. Cancer Inst., 31, 329-345.
145. Han Z. Q., Assenberg M., Liu B. L., Wang Y. B., Simpson G. S., Thoma S. and. Coffin R. S. (2007): Development of a second-generation oncolytic herpes simplex virus expressing TNFalpha for cancer therapy. J. Gene Med., 9, 99-106.
146. Hannay J., Davis J. J., Liu D., Fang B., Pollock R. E. and Lev D. (2007): Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther., 14, 671-681.
147. Hansen R. M and Libnoch J. A. (1978): Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch. Int. Med., 138, 1137-1138.
148. Haralambieva I., Iankov I., Hasegawa K., Harvey M., Russell S. J. and Peng K. W. (2007): Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther., 15, 588-597.
149. Harbour D. V., Galin F., Hughes K., Smith E. M. and Blalok J. E. (1991): Role of leukocyte-derived pre-opiomelanocortin peptids in endotoxin shock. Cit. Shock 35, 181-191.
150. Hasegawa K., Nakamura T., Harvey M., Ikeda Y., Oberg A., Figini M., Canevari S., Hartmann L. C. and Peng K. W. (2006): The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin. Cancer Res., 12, 6170-6178.
151. Hawkins L. K. and Kirn D. (2002): Oncolytic viruses: virotherapy for cancer. In Maruta E. (ed.): Tumor - Suppressing Viruses, Genes, and Drugs. Academic Press, San Diego-San Francisco-New York, 1-30.
152. He F., Ligeng L., Dooha K., Wen B., Deng X., Gutin P. H., Ling C. C. and Li C.C. (2007): Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res., 67, 634-642.
153. Healthcare Scientific Council (1998): The Healthcare Scientific Council's position on the anti-cancer examinations of Newcastle disease virus in our country. Orvosi Hetilap (in Hungarian) 139, 2903-2905.
154. Herrero Y., Calle M., Cornelis J. J., Herold-Mende C., Rommealere J., Schlehofer J. R. and Geletneky K. (2004): Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int. J. Cancer, 109, 76-84.
155. Hersey P. (2005): Vaccinia viral lysate in immunotherapy of melanoma. In Sinkovics L. G. and Horvath J. C. (eds.): Viral Therapy of Human Cancers. Marcel Dekker, New York, 697-712.
156. Hersey P., Coates A. S., McCarthy W. H., Thompson J. F., Sillar E. W., McLeod R., Gill P. G, Coventry B. J., McMullen A., Dillon H. and Simes H. J. (2002): Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol., 20, 4181-4190.
157. Hesse A. D., Kosmides D., Kontermann R. E. and Nettelbeck D. M. (2007): Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob protein. J. Virol., 81, 2688-2699.
158. Higgins G. K. and Pack G. T. (1951): The effects of virus therapy on the microscopic structure of human melanoma. Am. J. Pathol., 24, 728-729.
159. Higgins G. K. and. Pack G. T. (1951): Virus therapy in the treatment of tumors. Bull. Hosp. Joint Dis., 12, 379-382.
160. Hirasawa K., Nishikawa S. G., Norman K. L., Alain T., Kossakowa A. and Lee P. W. (2002): Oncolytic reovirus against ovarian and colon cancer. Cancer Res., 62, 1696-1701.
161. Hoffmann D., Bangen J. M., Bayer W. and Wildner O. (2006): Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther., 13, 1534-1544.
162. Hoffmann D., Bayer W., Grunwald T. and Wildner O. (2007): Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer. Mol. Cancer Ther., 6, 1942-1950.
163. Hoffmann D., Bayer W. and Wildner O. (2007): Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. Hum. Gene Ther., 18, 435-450.
164. Hoffmann D., Grunwald T., Kuate S. and Wildner O. (2007): Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy. Cancer Biol. Ther., 6, 510-518.
165. Horvath J. C. (2005: Newcastle disease virus: its oncolytic properties. In Sinkovics J. G. and J. C. Horvath J. C. (eds.): Viral Therapy of Human Cancers. Marcel Dekker, New York, 533-574.
166. Horvath J., Horak A. and Sinkovics J. G. (1995): Comparison of oncolytic Newcastle virus strains. Proceedings 86th Annual Meeting American Association Cancer Resaerch, Toronto, Canada, 36, 439 (abstract #2619).
167. Horvath J. C., Horak A., Sinkovics J. G., Pritchard M., Pendleton S. and Horvath E. (1999): Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine. Acta Microbiol. Immunol. Hung. 46, 1-20.
168. th Jubilee issue: Acta Microbiol Immunol. Hung., 50, 250-251.
169. Horvath J. C., Vega V., Lay S. and Sinkovics J. G. (2005): Oncolytic viruses kill tumor cells directly and indirectly. In: Abstracts, Third International Meeting Oncolytic Viruses as Cancer Therapeutics. Banff, Canada, March 9-13, 2005, p. 18.
170. Hotte S. J., Lorence R. M., Hirte H. W., Polawski S. R., Bamat M. K., O'Neil J. D., Roberts M. S., Groene W. S. and Major P. P. (2007): An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res., 13, 977-985.
171. Hu J. C., Coffin R. S., Davis C. J., Graham N. J., Groves N., Guest P. J., Harrington K. J., James N. D., Love C. A., McNeish I., Medley L. C., Michael A., Nutting C. M., Pandha H. S., Shorrock C. A., Simpson J., Steiner J., Steven N. M., Wright D. and Coombes R. C. (2006): A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 12, 6737-6747.
172. Hu Y., He Y., Srivenugopal K. S., Fan S. and Jiang Y. (2007): In vitro antitumor cytotoxic T lymphocyte response induced by dendritic cells transduced with ΔNp73α alpha recombinant adenovirus. Oncol. Rep., 18, 1085-1091.
173. Huang T. G., Ebert O., Shinozaki K., García-Sastre A. and Woo S. L. (2003): Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immunocompetent mice. Mol. Ther., 8, 434-440.
174. Huang Y. Y., Yu Z., Lin S. F., Li S., Fong Y. and Wong R. J. (2007): Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J. Clin. Endocrinol. Metab., 92, 1965-1970.
175. Hunter-Craig I., Newton K. A., Westbury G. and Lacey B. W. (1970): Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br. Med. J., 2, 512-515.
176. Iankov I. D., Blerchacz B., Liu C., Schmeckpeper J. D., Tarara J. E., Federspiel M. J., Caplice N. and Russell S. J. (2007): Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther., 15, 114-122.
177. Ikeda Y., Nishimura G., Yanoma S., Kubota A., Furukawa M. and Tsukada M. (2004): Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx, 31, 407-412.
178. Indraccolo S., Moserle L., Tisato V., Gola E., Minuzzo S., Roni V., Persano L., Chieco-Bianchi L. and Amadori A. (2006): Gene therapy of ovarian cancer with IFN-alpha - producing fibroblasts: comparison of constitutive and inducible vectors. Gene Ther., 13, 953-965.
179. Ioannides C. G., Platsoucas C. D. and Freedman R. S. (1990): Immunological effects of tumor vaccines. II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo, 4, 17-24.
180. Ioannides C. G., Platsoucas C. D., Patenia R., Kim Y. P., Bowen J. M., Morris M., Edwards C., Wharton J. T. and Freedman R. S. (1990): T cell function in ovarian cancer patients treated with viral oncolysates. I. Increased helper activity to immunoglobulin production. Anticancer Res., 10, 645-654.
181. Irving C. for Freeman A.I., Zakay-Rones Z., Gomori J. M., Linetsky E., Rasooly L., Greenbaum E., Rozenman--Yair S., Panet A., Libson E., Irving C. S., Galun E. and Siegal T. (2007): Intravenous NDV HUJ in recurrent glioblastoma - a phase I/II trial. The 4th International Conference on Oncolytic Viruses and Cancer Therapeutics Abstracts, p 21.
182. Israyelyan A. H., Melancon J. M., Lomax L. G., Sehgal I., Leuschner C., Kearney M. T., Chouljenko V. N., Baghian A. and Kousoulas K. G. (2007): Effective treatment of human breast tumor in mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytia mutation enabling high viral replication and spread in breast cancer cells. Hum. Gene Ther., 18, 457-473.
183. Itamochi H., Kigawa J., Kanamori Y., Oishi T., Bartholomeus C., Nahta R., Esteva F. J., Sneige N., Terakawa N. and Ueno N. T. (2007): Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol. Cancer Ther., 6, 227-235.
184. Ito H., Aoki H., Kühnel F., Kondo F. Y., Kubicka S., Wirth T., Iwado E., Iwamaru A., Fujuwara K., Hess K. R., Lang F. F., Sawaya R. and Kondo S. (2006): Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst., 98, 625-636.
185. Ito Y., Komada H., Kusagawa S., Tsurudome M., Matsumura H., Kawano M., Ohta H. and Nishio M. (1992): Fusion regulation proteins on the cell surface isolation and characterization of monoclonal antibodies which enhance giant polykaryocyte formation in Newcastle disease virus-infected cell lines of human origin. J. Virol., 66, 5999-6007.
186. Jäger E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., Ayyoub M., Ritter E., Jäger D., Panicali D., Hoffmann E., Pan L., Oettgen H., Old L. J. and Knuth A. (2006): Recombinant vaccinia/fowlpox NY-ESO-1 vaccine induces both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA, 103, 14453-14458.
187. Jakubczak J. L., Ryan P., Gorziglia M., Clarke L., Hawkins L. K., Hay C., Huang Y., Kaloss M., Marinov A., Phipps S., Pinkstaff A., Shirley P., Skripchenko Y., Stewart D., Forry-Schaudies S. and Hallenbeck P. L. (2003): An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors. Cancer Res., 63, 1490-1499.
188. Jestin V. and Cherbonnel M. (1991): Interferon-induction in mouse spleen cells by the Newcastle disease virus (NDV) HN protein. Ann. Rech. Vet., 22, 365-372.
189. Jeyaretna D. S., Rabin S. D. and Martuza R. L. (2007): Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg. Focus, 22, E4.
190. Jiang H. C., Gomez-Manzano C., Aoki H., Alonso M. M., Kondo S., McCormick F., Xu J., Kondo Y., Bekele B. N., Colman H., Lang F. F. and Fueyo J. (2007): Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst., 99, 1410-1414.
191. Jiang H. F., McCormick F., Lang F. F., Gomez-Manzano C. and Fueyo J. (2006): Oncolytic adenoviruses as antiglioma agents. Expert Rev. Anticancer Ther., 6, 697-708.
192. Jiang H., Meng Q., Tan H., Pan S., Sun B., Xu R. and Sun X. (2007): Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int. J. Cancer, 12, 416-424.
193. Jiang H., White E. J., Gomez-Manzano C. and Fueyo J. (2008): Adenovirus's last trick: you say lysis, we say autophagy. Autophagy, 4, 118-120.
194. Kaiserlian D., Grosjean I. and Caux C. (1997): Infection of human dendritic cells by measles virus induces immune suppression. Adv. Exp. Med. Biol., 417, 421-423.
195. Kanai R., Tomita H., Hirose Y., Ohba S., Goldman S., Okano H., Kawase T. and Yazaki T. (2007): Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum. Gene Ther., 18, 63-73.
196. Kasuya H., Nishiyama Y., Nomoto S., Goshima F., Takeda S., Watanabe I., Nomura N., Shikano T., Fujii, T., Kanazumi N. and Nakao A. (2007): Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther., 14, 533-542.
197. Kawa A. and Arakawa S. (1987): The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn. J. Exp. Med., 57, 79-81.
198. Kay H. D., Bonnard G. D. West W. H. and Herberman R. B. (1977): A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J. Immunol., 118, 2058-2066.
199. Kemeny N., Brown K., Covey A., Kim T., Bhargava A., Brody L., Guilfoyle B., Haag N. P., Karrasch M., Glassschroeder B., Knoll A., Getrajdman G., Koval K. J., Jarnagin W. R. and Fong Y. (2006): Phase I, open-label, dose escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinomas to the liver. Hum. Gene Ther., 17, 1214-1224.
200. Kenney S. and Pagano J. S. (1994): Viruses as oncolytic agents: a new age for "therapeutic" viruses? J. Natl. Cancer Inst., 86, 1185-1186.
201. Kim E. M., Sivanandham M., Stavropoulos C. I., Bartolucci A. A. and Wallack M. K. (2001): Overview analysis of adjuvant therapies for melanomas - a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials. Surg. Oncol., 10, 53-59.
202. Kim J., Kim J. H., Choi K. J., Kim P. H. and Yun C. O. (2007): E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum. Gene Ther., 18, 773-786.
203. Kim J. H., Oh J. Y., Park B. H., Lee D. E., Kim J. S., Park H. E., Roh M. S., Je J. E., Yoon J. H., Thorne S. H., Kirn D. and Hwang T. H. (2006): Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther., 14, 361-370.
204. Kim M. Y., Chung H. and Johnston R. N. (2007): Reovirus and tumor oncolysis. J. Microbiol., 45, 187-192.
205. Kim M., Egan C., Alain T., Urbanski S. J., Lee P. W., Forsyth P. A. and Johnston R. N. (2007): Acquired resistance to reoviral oncolysis in ras-transformed fibrosarcoma cells. Oncogene, 26, 4124-4134.
206. King G. D., Muhammad A. G., Xiong W., Kroeger K. M., Puntel M., Larocque D., Palmer D., Ng P., Lowenstein P. R. and Castro M. G. (2008): High-capacity adenoviral vector-mediated anti-glioma gene therapy in the presence of systemic anti-adenovirus immunity. J. Virol., 82, 4680-84.
207. Kirchner H. H., Anton P. and Atzpodien J. (1995): Adjuvant treatment of locally advanced renal cell cancer with autologous virus-modified tumor vaccines. World J. Urol., 13, 171-173.
208. Kirn D. H., Wang Y. Le Boef F., Bell J. and Thorne S. H. (2007): Targeting of interferon-beta to produce a specific, multimechanistic oncolytic vaccinia virus. PLoS Med., 4, e353.
209. Kirn D. H., Wang Y., Liang W., Contag C. H. and Thorne S. H. (2008): Enhancing poxvirus oncolytic effects through increased spread and immune events. Cancer Res., 68, 2071-2075.
210. Kobayashi H., Sendo F., Shirai T., Kaji H. and Kodama T. (1969): Modification of growth of transplantable rat tumors exposed to Friend virus. J. Natl. Cancer Inst., 42, 413-419.
211. Koch A. S. and Tarnai T. (1988): The aestetics of viruses. Leonardo, 2, 161-166.
212. Koketsu S., Watanabe T., Kazama S., Ishihara S. and Komuro Y. (2004): What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology, 51, 1648-1652.
213. Koprowski H., Love R. and Koprowska I. (1957): Enhancement of susceptibility to viruses in neoplastic tissues. Texas Rep. Biol. Med., 15, 111-128.
214. Kottke T., Galivo F., Wongthida P., Maria Diaz M., Thompson J, Jevremovic D., Barber G. N., Hall G., Chester J., Selby P., Harrington K., Melcher A. and Vile R. G. (2008): Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther., 16, 1217-1226.
215. Kovamees J., Norrby E. and Elango N. (1989): Complete nucleotide sequence of the hemagglutinin-neuramidase (HN) mRNA of mumps virus and comparison of paramyxovirus HN proteins. Virus Res., 12, 87-96.
216. Kuroda T., Rabkin S. D. and Martuza R. L. (2006): Effective treatment of tumors with strong beta-catenin/T - cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res., 66, 10127-10135.
217. Kurooka M. and Kaneda Y. (2007): Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res., 67, 227-236.
218. Kurozimi K., Hardcastle J., Thakur R., Yang M., Christoforidis G. G., Fulci G., Hochberg F. H., Weissleder R., Carson W., Chiocca E. A. and Kaur B. (2007): Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst., 99, 1768-1781.
219. Lam K. M. and Hao Q. (1987): Induction of lymphocyte agglutination and lysis by Newcastle disease virus. Vet. Microbiol., 15, 49-56.
220. Lam K. M. and Vasconcelos A. C. (1994): Newcastle disease virus-induced apoptosis in chicken peripheral blood lymphocytes. Vet. Immunol. Immunopathol., 44, 45-56.
221. Lee P. W. K. (2002): Reovirus therapy of Ras-associated cancers. In Maruta H. (ed.): Tumor-Suppressing Viruses, Genes and Drugs. Academic Press, San Diego-San Francisco-New York, 31-43.
222. Li H., Dutuor A., Tao L., Fu X. and Zhang X. (2007): Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res., 13, 316-322.
223. Li H., Zeng Z., Fu X. and Zhang X. (2007): Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune response. Cancer Res., 67, 7850-7855.
224. Li L., Scudiero D., Miller S. A., Yu Z. X., Stukenberg P. T., Shoemaker R. H. and Kotin R. M. (2007): Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther., 14, 814-827.
225. Li N., Zhou J., Weng D., Zhang C., Li L., Wang B., Song Y., He Q., Lin D., Chen D., Chen G., Gao Q., Wang S., Xu G., Meng L., Lu Y. P. and Ma D. (2007): Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 13, 5847-5854.
226. Li Q. X., Yu D. H., Liu G., Ke N., McKelvy J. and Wong-Staal F. (2008): Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ., 15,1197-1210.
227. Li W. X., Li H., Li F., Dus M., Atkinson P., Brydon F. W., Johnson K. L., García-Sastre A., Ball L. A., Palese P. and Ding S. W. (2004): Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc. Natl. Acad. Sci. USA, 101, 1350-1355.
228. Li X., Jin N., Mi Z., Lian H., Sun L., Li X. and Zheng H. (2006): Antitumor effects of a recombinant fowlpox virus expressing apoptin in vivo and in vitro. Int. J. Cancer, 119, 2948-2957.
229. Li Z., Sergel T., Razvi E. and Morrison T. (1998): Effect of cleavage mutants on syncytium formation directed by the wild-type fusion protein of Newcastle disease virus. J. Virol., 72, 3789-3795.
230. Liang W., Wang W., Sun T.-M., Yao W.-Q., Chen L.-L., Jin Y., Li C.-L. and Meng F. J. (2003): Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol., 9, 495-498.
231. Libertini S., Iacuzzo I., Ferraro A., Vitale M., Bifulco M., Fusco A. G. and Portella G. (2007): Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology, 11, 5186-5194.
232. Lichty B. D., Power A.T., Stojdl D. F. and Bell J. C. (2004): Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med., 10, 210-216.
233. Linardakis E., Bateman A., Phan V., Ahmed A., Gough M., Olivier K., Kennedy R., Errington F., Harrington K. J., Melcher A. and Vile. R. (2002): Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res., 62, 5495-5504.
234. Lindenmann J. and Klein P. A. (1967): Immunological Aspects of Viral Oncolysis. Springer Verlag, Berlin -Heidelberg-New York, 1-84.
235. Liu T.-C., Galanis E. and Kirn D. (2007): Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol., 4, 101-117.
236. Liu T.-C., Wakimoto H., Martuza R. L. and Rabkin S. D. (2007): Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3 - kinase-Akt-targeting molecular therapeutics. Clin. Cancer Res., 13, 5897-5902.
237. Liu T.-C., Zhang T., Fukuhara H., Kuroda T., Todo T., Martuza R. L., Rabkin S. D. and Kurtz A. (2006): Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol. Ther., 14, 789-797.
238. Lopes L., Fletcher K., Ikeda Y. and Collins M. (2006): Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother., 55, 10110-1016.
239. Lorence R. M., Reichard R. W., Katubig B. B., Reyes H. M., Phuangsab A., Mitchell B. R., Cascino C. J., Walter R. J. and Peeples M. E. (1994): Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst., 86, 1228-1233.
240. Lorence R. M., Roberts M. S., Groene W. S. and Rabin H. (2001): Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In Herrnáiz Driever P. and Rabkin D. S.: Replication-Competent Viruses for Cancer Therapy. H. W. Doerr's Monographs in Virology. Karger, Basel, 22, 160-182.
241. Lorence R. M., Roberts M. S., O'Neil J. D., Groene J. D., Miller J. A., Mueller S. N. and Bamat M. K. (2007): Phase I clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets, 7, 157-167.
242. Lukashov V. V. and Goudsmit J. (2001): Evolutionary relationship among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J. Virol., 75, 2729-2740.
243. Lun X., Senger D. L., Alain T., Oprea A., Parato K., Stjodl D., Lichty B., Power A., Johnston R. N., Hamiltion M., Parney I., Bell J. C. and Forsyth P. A. (2006): Effects of intravenously administered recombinant vesicular stomatitis virus (VSVdeltaM51) on multifocal and invasive gliomas. J. Natl. Cancer Inst., 98, 1546-1557.
244. Lun X., Yang, W., Alain T. Z., Shi Z.Q., Muzik H., Barrett J. W., McFaddeen G., Bell J., Hamilton M. G., Senger D. L. and Forsyth P. A. (2005): Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res., 65, 9982-9990.
245. Lun X. Q., Zhou H., Alain T., Sun B., Wang L., Barrett J. W., Stanford M. M., McFadden G., Bell J. and Forsyth P. A. (2007): Targeting human medulloblastoma: oncolytic virotherapy with myxomavirus is enhanced by rapamycin. Cancer Res., 67, 8818-8827.
246. Luo J., Xia Q., Zhang R., Lv C., Zhang W., Wang Y., Cui Q., Liu L., Cai R. and Qian C. (2008): Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer Res., 14, 2450-2457.
247. Mahller Y. Y., Vaikunth S. S., Currier M. A., Miller S. J., Ripberger M. C., Hsu Y. H., Mehrian-Shai R., Collins M. H., Cromleholme T. M., Ratner N. and Cripe T. P. (2007): Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther., 1, 279-286.
248. Malerba M., Daeffler L., Rommelaere J. and Iggo R. D. (2003): Replicating parvoviruses that target colon cancer cells. J.Virol., 77, 6683-6691.
249. Marmelzat W. L. (1968): Malignant tumors in smallpox vaccination scars: a report of 24 cases. Arch. Dermatol., 97, 400-406.
250. Marshall J. L., Gulley J. L., Arlen P. M., Beetham P. K., Tsang K. Y., Slack R., Hodge J. W., Doren S., Grosenbach D. W., Hwang J., Fox, E., Odogwu L., Park S., Pancalui D. and Schlom J. (2005): Phase I study of sequential vaccination with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccine-CEA(6D)-TRICOM with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol., 23, 720-231.
251. Mastrangelo M. J., Maguire M. C., Eisenlohr L. C., Laughlin C. E., Monken C. E., McCue P. A., Kovatich A. J. and Lattime E. C. (1999): Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., 6, 409-422.
252. Merrill M. D., Solecki D. and Gromeier M. (2005): Poliovirus recombinants against malignant glioma. In Sinkovics J. G. and Horvath J. C. (eds): Viral Therapy of Human Cancers. Marcel Dekker, New York, 739-779.
253. Mi Y. X., Long Y. H. and Li Y. C. (2008): Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment. World J. Gastroenterol., 14, 1321-1325.
254. Millar N. S., Chambers P. and Emmerson P. T. (1988): Nucleotide sequence of the fusion and haemagglutinin-neuraminidase glycoprotein genes of Newcastle disease virus, strain Ulster: molecular basis for variations in pathogenicity between strains. J. Gen. Virol., 69, 613-620.
255. Mitlianga P. G., Sioka C., Vartholomatos G., Goussia A., Polyzoidis K., Rao J. S. and Kyritsis A. P. (2006): p53 enhances the delta-24 conditionally replicative adenovirus anti-glioma effect. Oncol. Rep., 15, 149-153.
256. Moehler M. H., Zeidler M., Wilsberg V., Cornelis J. J., Woelfel T., Rommelaere J., Galle P. R. and M. Heike M. (2005): Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther., 16, 996-1005.
257. Mok W., Boucher Y. and Jain R. K. (2007): Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res., 67, 10664-10668.
258. Moore A. E. (1949): Effect of inoculation of the viruses of influenza A and herpes simplex on the growth of transplantable tumors in mice. The destructive effect of the virus of Russian Far east encephalitis on the transplantable mouse sarcoma. Cancer, 2, 516-534.
259. Moore A. E. (1957): Oncolytic properties of viruses. Texas Rep. Biol. Med., 15, 140-145.
260. Moore A. E. (1960): The oncolytic viruses. Progr. Exp. Tumor Res., 1, 411-439.
261. Moss R. W. (1996-1999). MTH-68. Center for Alternative Medicine Research in Cancer Home Page. http:/www.sph.uth.tmc.edu/utcam.therapies/mth68.htm.
262. Muceniece A. Y. (1972): Onkotropism Virusov i Problema Viroterapii Zlokachestvennnih Opuholei (in Russian). Oncotropism of Viruses and the Problem of Virotherapy of Malignant Tumors. Zinatne, Riga, Latvia, 9-443.
263. Mullen J. T. and Tanabe K. K. (2002): Viral oncolysis. Oncologist, 7, 106-119.
264. Murugesan S. R., Akiyama M., Einfeld D. A., Wickham T. J. and King C. R. (2007): Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor. Int. J. Oncol., 31, 813-822.
265. Muster T., Rajtarova J., Sachet M., Unger H., Fleischhacker R., Romirer I., Grassauer A., Url A., García-Sastre A., Wolff K., Pehamberger H. and Bergmann M. (2004): Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int. J. Cancer, 110, 15-21.
266. Nász I. and Ádám É. (2006): Symmetry types, systems and their multiplicity in the structure of adenovirus capsid. I. Symmetry networks and general symmetry motifs. Acta Microbiol. Immunol. Hung., 53, 1-23.
267. Nász I. and Ádám É. (2006): Symmetry types, systems and their multiplicity in the structure of adenovirus capsid. II. Rotational facet groups of five-, three-, and two-fold symmetry axes. Acta Microbiol. Immunol. Hung., 53, 115-133.
268. Natesan S., Kataria J. M., Dhama K., Bhardwaj N. and Sylvester A. (2006): Anti-neoplastic effect of chicken anemia virus VP3 protein (apoptin) in Rous sarcoma virus - induced tumours in chicken. J. Gen. Virol., 87, 2933-2940.
269. Nemunaitis J., Senzer N., Sarmiento S., Zhang Y.A., Arzaga R., Sands B., Maples P. and Tong A. W. (2007): A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther., 14, 885-893.
270. Nettelbeck D. M., Rivera A. A., Balagué C., Alemany R. and Curiel D. T. (2002): Novel oncolytic adenoviruses targeted to melanoma. Cancer Res., 62, 4663-4670.
271. Nienhuis A. W. (2008): Development of gene therapy for blood disorders. Blood, 111, 4431-4444.
272. Nishiyama Y., Ito Y., Shimokata K., Kimura Y. and Nagata I. (1976): Polykaryocyte formation induced by VSV in mouse cells. J. Gen. Virol., 32, 85-96.
273. Nordström I., Nurkkala M., Collins L. V. and Eriksson K. (2005): CD8+ cells suppress antigen-specific and allogeneic CD4+ T cell responses to herpes simplex virus type 2-infected human dendritic cells. Viral Immunol., 18, 616-626.
274. Norman K. L., Coffey M. C., Hirasawa K., Demetrick D. J., Nishikawa S. G., DiFrancesco L. M., Strong J. E. and Lee P. W. (2002): Reovirus oncolysis of human breast cancer. Hum. Gene Ther., 13, 641-652.
275. Norman K. L., Hirasawa K., Yang A. D., Shields M. and Lee P. W. (2004): Reovirus oncolysis: the Ras/Ral/GEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. USA, 101, 11099-11104.
276. Noser J. A., Mael A. A., Sauma R., Ohmine S., Marcato O. P., Lee P. W. and Ikeda Y. (2007): The Ras/Raf1/ /Mek/Erk signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol. Ther., 15, 1531-1536.
277. Numnum T. M., Makhija S., Lu H., Wang M., Rivera A., Stoff-Khalili M., Alvarez R. D., Zhu Z. B. and Curiel D. T. (2008): Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol. Oncol., 108, 34-41.
278. Nüesch J. P. and Rommelaere J. (2007): A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc. Natl. Acad. Sci. USA, 104, 12482-12487.
279. Ochiai H., Campbell S. A., Aecher G. E., Chewning T. A. Dragunsky E., Ivanov A., Gromeier M. and Sampson J. H. (2006): Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res., 12, 1349-1354.
280. Okamoto K., Ohgimoto S., Nishio M., Tsurudome M., Kawano M., Komada H., Ito M., Sakakura Y. and Ito Y. (1997): Paramyxovirus-induced syncytium cell formation is suppressed by a dominant negative fusion regulatory protein-1 (FRP 1)/(CD98) mutated construct: an important role of FRP-1 in virus-induced cell fusion. J. Gen. Virol., 78, 775-783.
281. Olijslagers S. J., Zhang Y. H., Backendorf C. and Noteborn M. H. (2007): Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin. Pharmacol. Toxicol., 100, 127-131.
282. Özduman K., Wollman G., Piepmeietr J. P. and van den Pol A. (2008): Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci., 28, 1882-1893.
283. Pack G. T. (1950): Note on the experimental use of rabies vaccine for melanomatosis. Arch. Dermatol. Syphil., 62, 694-695.
284. Padgett B. L. and Walker D. L. (1970): Effect of persistent fibroma virus infection on susceptibility of cells to other viruses. J. Virol., 5, 199-204
285. Page J. G., Tian B., Schweikart K., Tomaszewski J., Harris R., Broadt T., Polley-Nelson J., Noker P. E., Wang M., Makhija S., Aurigemma R., Curiel D. T. and Alvarez R. D. (2007): Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5 - delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am. J. Obstet. Gynecol., 196, 1-9.
286. Paglino J., Burnett E. and Tattersall P. (2007): Exploring the contribution of distal P4 promoter elements to the oncoselectivity of minute virus of mice. Virology, 361, 174-184.
287. Pajtasz-Piasecka E., Rossowska J., Duoe D., Weber--Da̧browska B., Zabłocka A. and Górski A. (2008): Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett., 116, 24-32.
288. Palena C., Foon K.A., Panicali D., Yafal A.G., Chinsangaram J., Hodge J. W., Schlom J. and Tsang K. Y. (2005): Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood, 106, 3515-3523.
289. Palmowski M. J., Lopes L., Ikeda Y., Salio M., Cerundolo V. and Collins M. K. (2004): Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol., 172, 1582-1587.
290. Paraskevakou G., Allen C., Nakamura T., Zollman P., James C. D., Peng K. W., Schroeder M., Russell S. J. and Galanis E. (2007): Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGF-R/EGFRvIII expressing gliomas. Mol. Ther., 15, 677-686.
291. Parato K., Senger D., Forsyth P. A. and Bell J. C. (2005): Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer, 5, 965-976.
292. Parney I. F., Chang L. J., Farr-Jones M. A., Hao C., Smylie M. and Petruk K. C. (2006): Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J. Neurooncol., 78, 71-80
293. Pecora A. L., Rizvi N., Cohen G. I., Meropol N. J., Sternman D., Marshall J. L., Goldberg S., Gross P., O'Neil J. D., Groene W. S., Roberts M. S., Rabin H., Bamat M. K. and Lorence R. M. (2002): Phase I trial of intravenous administration of PV701, an oncolytic virus in patients with advanced solid cancers. J. Clin. Oncol., 20, 2251-2266. 294.
294. Perros M., Deleu L., Vanacker J. M., Kherrouche Z., Spruyt N., Faisst S. and Rommelaere J. (1995): Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells. J. Virol., 69, 5506-5515.
295. Peters C. J. (2006): Lymphocytic choriomeningitis virus - an old enemy up to new tricks. N. Engl. J. Med., 354, 2208-2211.
296. Peterson P. K., Molitor T.W. and Chao C. C. (1998): The opioid-cytokine connection. J. Neuroimmunol., 83, 63-69.
297. Piskurek O. and Okada N. (2007): Poxviruses as possible vectors for horizontal transfer of retroposons from reptiles to mammals. Proc. Natl. Acad. Sci. USA, 104, 12046-12051.
298. Plaksin D., Porgador A., Vadai E., Feldman, M., Schirrmacher V. and Eisenbach L. (1994): Effective anti-melanoma vaccination with tumor cells transfected with MHC gene and/or infected with Newcastle disease virus. Int. J. Cancer, 59, 796-801.
299. Porosnicu M., Mian A. and Barber G. N. (2003): The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/ uracil phosphoribosyltransferase suicide gene. Cancer Res., 63, 8366-8376.
300. Post D. E., Sandberg E. M., Kyle M. M., Devi N. S., Brat D. J., Xu Z., Tighiouart M. and Van Meir E. G. (2007): Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res., 67, 6872-6881.
301. Qiao J., Wang H., Kottke T., Diaz R.M., Willmon C., Hudaczek A., Thompson J., Parato K., Bell J., Naik J., Chester J., Selby P., Harrington K., Melcher A. and Vile R.G. (2008): Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gen Ther., 15, 604-616.
302. Qin Z. M., Tan L. T., Xu H. Y., Ma B. C., Wang Y. L., Yuan X. Y. and Liu W. J. (2008): Pathotypical characterization and molecular epidemiology of Newcastle disease virus isolates from different hosts in China from 1996 to 2995. J. Clin. Microbiol., 46, 601-611.
303. Quirin C., Mainka A., Hesse A. and Nettelbeck D. M. (2007): Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int. J. Cancer, 121, 2801-2807.
304. Raftery M. J., Behrens C. K., Müller A., Krammer P. H., Walczak H. and Schönrich G. (1999): Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J. Exp. Med., 190, 1103-1114.
305. Rajecki M., Kanerva A., Stenman U. H., Tenhunen M., Kangasniemi L., Särkioja M., Ala-Opas M. Y., Alfthan H., Sankikla A., Rintala E., Desmond R. A., Hakkarainen T. and Hemminki A. (2007): Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol. Cancer Ther., 6, 742-751.
306. Raki M. R., Hakkarainen T., Bauerschmitz G. J., Särkioja M., Desmond R. A., Kanerva A. and Hemminki A. (2007): Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus Gene Ther., 14, 1380-1388.
307. Raki M., Särkioja M., Desmond R. A., Chen D. T., Bützow R., Hamminki A. and Kanerva A. (2007): Oncolytic adenovirus Ad5/3 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol. Oncol., 108, 166-172.
308. Raykov Z., Grekova S., Galabov A. S., Balboni G., Koch U., Aprahamian M. and Rommelaere J. (2007): Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol. Rep., 17, 1493-1499.
309. Raykov Z., Grekova S., Leuchs B., Aoprahamian M. and Rommelaere J. (2008): Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int. J. Cancer, 122, 2880-2884.
310. Raykov Z., Savelyeva L., Balboni G., Giese T., Rommelaere J. and Giese N. A. (2005): B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype expression. J. Virol., 79, 3517-3524.
311. Reagan R. L., Delaha E. C. and Brueckner A. L. (1955): Electron micrograph of Negri bodies found in rabies. Texas Rep. Biol. Med., 13, 157-161.
312. Reddy P. S., Burroughs K. D., Hales L. M., Ganesh S., Jones B. H., Idamakanti N., Hay C., Li S. S., Skele K. L., Vasko A.-J., Yang J., Watkins D. N., Rudin C. M. and Hallenbeck P. L. (2007): Seneca valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J. Natl. Cancer Inst., 99, 1623-1633.
313. Reid V., Yu Z., Schuman T., Li S., Singh P., Fong Y. and Wong R. J. (2008): Herpes oncolytic therapy of salivary gland carcinomas. Int. J. Cancer, 122, 202-258.
314. Rhim J. H. and Tosato G. (2007). Targeting the tumor vasculature to improve the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst., 99, 1739-1741.
315. Ring C. J. (2002): Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol., 83, 491-502.
316. Rohn J. L. and Noteborn M. H. (2004): The viral death effector apoptin reveals tumor-specific processes. Apoptosis, 9, 315-322.
317. Ruscetti S., Davis L., Field J. and Oliff A. (1981): Friend murine leukemia virus-induced leukemia is associated with the formation of mink cell focus-inducing viruses and is blocked in mice expressing endogenous mink cell focus - inducing xenotropic viral envelope genes. J. Exp. Med., 154, 907-920.
318. Russell P. H. and Koch G. (1993): Local antibody forming cell responses to Hitchner B1 and Ulster strains of Newcastle disease virus. Vet. Immunol. Immunopathol., 37, 165-189.
319. Russell S. J. (2002): RNA viruses as virotherapy agents. Cancer Gene Ther., 9, 961-966.
320. Russell S. J. (2005): Measles virus: a potent, versatile, retargetable oncolytic platform. In AACR Education Book. AACR 96th Annual Meeting, 389s-394s.
321. Sabin A. (1957): Discussion. Texas Rep. Biol. Med., 15, 151-153.
322. Salmon et Baix P. (1922): Vaccine variolique dans le cancer. C. R. Soc. Biol., 86, 819-820.
323. Sarkar D., Lebedeva I. V., Su Z. Z., Park E.-S., Chatman L., Vozhilla N., Dent P., Curiel D. T. and Fisher P. B. (2007): Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res., 67, 5434-5442.
324. Sarkar D., Su Z. Z., Park E. S., Vozhilla N., Dent P., Curiel D. T. and Fisher P. B. (2008): A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther., 15, 293-302.
325. Sartorius R., Pisu P., D'Apice L., Pizzella L., Romano C., Cortese G., Giorgini A., Santoni A., Velotti F. and DeBerardinis P (2008): The use of filamentous bacteriophage fd to deliver MAGE-A10 and MAGE-A3 HLA - A2-restricted peptides and to induce strong antitumor CTL responses. J. Immunol., 180, 3719-3728.
326. Sato H., Oh-hira M., Ishida N., Imamura Y., Hattori S. and Kawakita M. (1987): Molecular cloning and nucleotide sequence of P, M, and F genes of Newcastle virus avirulent strain D26. Virus Res., 7, 241-255.
327. Satoh M., Wang H., Ishidoya S., Abe H., Moriya T., Hamada H. and Arai Y. (2007): Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. Urology, 70, 1243-1248.
328. Särkioja M., Pesonen S., Raki M., Hakkarainen T., Salo J., Ahonen M. T., Kanerva A. and Hemminki A. (2008): Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther., 15, 921-929.
329. Schattner A. (1984): Therapeutic role of measles vaccine in Hodgkin's disease. Lancet, 1, 171.
330. Schepelmann S., Ogilvie L. M., Hedley D., Friedlos F., Martin J., Scanlon I., Chen P., Marais R. and Springer C. J. (2007): Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res., 67, 4949-4955
331. Schierer S., Hess A., Müller I., Kampgen E., Curiel D.T., Schuler G., Steinkasserer A. and Nettelbeck D. M. (2008): Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Int. J. Cancer, 122, 219-229.
332. Schirrmacher V. (2005): Antitumor immune memory and its activation for control of residual tumor cells and improvement of patient survival. A new concept derived from translational research with the virus-modified tumor vaccine ATV-NDV. In Sinkovics J. G. and Horvath J. C. (eds.): Viral Therapy of Human Cancers. Marcel Dekker, New York, 481-531
333. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R. and Ertel C. (1999): Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther., 6, 63-73.
334. Schirrmacher V., von Hoegen P., Schlag P., Liebrich W., Lehner B., Schumacher K., Ahlert T. and Bastert G. (1989): Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. In Schirrmacher V. and Schwarz-Albie R. (eds.): Cancer Metastasis. Springer Verlag, Berlin-Heidelberg-New York, 157-170.
335. Schneider U., Bullough F., Vongpunsawead S., Russell S. J. and Cattaneo R. (2000): Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol., 74, 9928-9936.
336. Seal B. S., King D. J., Locke D. P., Senne D. A. and Jackwood M. W. (1998): Phylogenetic relationships among highly virulent Newcastle disease virus isolates obtained from exotic birds and poultry from 1989 to 1996. J. Clin. Microbiol., 36, 1141-1145.
337. Sebestyén Z., de Vrij J., Magnusson M., Debets R. and Willemsen R. (2007): An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res., 67, 11309-11316.
338. Servais C., Caillet-Fauquet P., Draps M. L., Velu T., de Launoit T. and Brandenburger A. (2006): Hypoxic response element in the oncolytic parvovirus minute virus of mice do not allow for increased vector production in low oxygen tension. J. Gen. Virol., 87, 1197-1201.
339. Shah A. C., Parker G. N., Gillespie G. Y., Lakeman F. D., Meleth S., Markert J. M. and Cassady K. A. (2007): Enhanced antiglioma activity of chimeric HCM/HSV-1 oncolytic viruses. Gene Ther., 14, 1045-1054.
340. Shah K. V. (2007): SV40 and human cancer: a review of recent data. Int. J. Cancer, 120, 215-223.
341. Sharp B. M., Roy S. and Bidlack J. M. (1998): Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol., 83, 45-56.
342. Shawler D. L., Batholomew R. M., Garrett M. A., Trauger R. J., Dorigo O., Van Beveren C., Marchese A., Ferre F., Duffy C., Carol D. J., Sherman L. A., Gold D. P. and Sobol R. E. (2002): Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin. Exp. Immunol., 129, 99-106.
343. Shen F. B., Guo C. Y, Yi B., Luo Z. X., Li H. X. and Wang L. (2007): Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban, 38, 386-390.
344. Shi Z. Y., Ma C. W., Huang J., Lin W. M., Dong R. C. and Luo Z. Y. (1997): Inhibition of parvovirus H-1 on transplantable human hepatoma and its histological and histochemical studies. Shi Yan Sheng Wu Xue Bao, 30, 247-259.
345. Shimizu Y., Hasumi K., Okudaira Y., Yamanishi K. and Tanakahashi M. (1988): Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect. Prev., 12, 487-495
346. Shin E. J., Chang J. I., Choi B., Wanna G., Ebert O., Genden E. M. and Woo S. L. (2007): Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol. Head Neck Surg., 136, 811-817.
347. Simpson G. R., Han Z., Liu B., Wang Y., Campbell G. and Coffin R. S. (2006): Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res., 66, 4835-4842.
348. Sinkovics J. (1956): Die Grundlagen der Virusforschung. Verlag der Ungarischen Akademie der Wissenschaften, Budapest, 3-420.
349. Sinkovics J. (1957): Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborn mice. Arch. ges. Virusforsch., 7, 403-411.
350. Sinkovics J. (1957): The human pathogenicity of the Newcastle disease virus and its relationship to mumps, fowl plague and influenza viruses. Arch. ges. Virusforsch., 7, 242-257.
351. Sinkovics J. G. (1957): Enhancement of carcinostatic activity of Newcastle disease virus (NDV) associated with adaptation of NDV to suckling mouse brain. Bact. Proc., 57, 96.
352. Sinkovics J. G. (1968): Project M27 gm/13: Effect of oncolytic viruses in selected cases of human malignant diseases. Research Report. The University of Texas M.D. Anderson Hospital. Printing Division, The University of Texas, Austin, TX, 348-349.
353. Sinkovics J. G. (1973): Monitoring in vitro cell-mediated immune reactions to tumors. Methods Cancer Res., 8, 107-175.
354. Sinkovics J. G. (1976): Chapter 2. Immunology of tumors in experimental animals. In Harris J. E. and Sinkovics J. G. (authors): The Immunology of Malignant Disease. C. V. Mosby, Saint Louis, 93-282.
355. Sinkovics J. G. (1977): Immunotherapy with viral oncolysates for sarcoma. J. Am. Med Assoc., 237, 869.
356. Sinkovics J. G. (1983): Viral oncolysates for cancer therapy. In Jeljaszewicz J., Ludwig H. and Pulverer G. (eds): Proceedings 13th International Congress Chemotherapy, Plenary Lectures. Immunomodulation of Cancer by Bacterial Products. SS94-95 Part 225, 43-53.
357. Sinkovics J. G. (1987). A reappraisal of cytotoxic lymphocytes in human tumor immunology. In Cory J. G. and A. Szentivanyi A. (eds): Cancer Biology and Therapeutics. Plenum Press, New York- London, 225-253.
358. Sinkovics J. G. (2005): Progressive development of viral therapy of human cancers. In Sinkovics J. G. and Horvath J. C. (authors): Viral Therapy of Human Cancers. Marcel Dekker, New York, 1-147 and 162-168.
359. Sinkovics J. G. (2005): The predictive value of tissue culture and xenograft assays. In Sinkovics J. G. and Horvath J. C. (eds.): The Viral Therapy of Human Cancers. Marcel Dekker, New York, 320-396.
360. Sinkovics J. G. (2007): Adult human sarcomas. I. Basic science. Expert Rev. Anticancer Ther., 7, 31-56.
361. Sinkovics J. G. (2008): Cytolytic Immune Lymphocytes in the Armamentarium of the Human Host. Schenk Verlag Dialog Campus, Pécs & Budapest, Hungary, Passau, Germany, 1-400.
362. Sinkovics J. G., Cabiness J. R. and Shullenberger C. C. (1972): Disappearance after chemotherapy of blocking serum factors as measured in vitro with lymphocytes cytotoxic to tumor cells. Cancer, 30, 1428-1437.
363. Sinkovics J. G., Campos L. T., Kay H. D., Loh K. K., Cabiness J. R. and Ervin F. (1973): The concept of immunotherapy of human sarcomas: the need for an in vitro monitoring assay. Ann. Clin. Lab. Sci., 3, 414-423.
364. Sinkovics J. G., Groves G. F. and Howe C. D. (1968): Actions of interferon in tissue cultures harboring mouse leukemia virus. Experientia, 24, 927-928.
365. Sinkovics J. G., Gyorkey F., Cabiness J. R. and Keil D. (1972): Effect of mycoplasma contamination of target cells on the in vitro monitoring of cell- and antibody-mediated immune reactions of patients to cultured tumor cells. Ann. Meet Am. Soc. Microbiol., 72, 127 #M286.
366. Sinkovics J. G., Györkey F., Kusyk C. and Siciliano M. J. (1978): Growth of human tumor cells in established cultures. Methods Cancer Res., 14, 243-323.
367. Sinkovics J. G. and Harris J. E. (1976): Chapter 5. Immunology and immunotherapy of human tumors. In Harris J. E. and Sinkovics J. G. (authors): The Immunology of Malignant Disease. C. V. Mosby, Saint Louis, 410-579.
368. Sinkovics J. G. and Horvath J. C. (1995): Can virus therapy of human cancer be improved by apoptosis induction? Med. Hypothes, 44, 359-368.
369. Sinkovics J. G. and Horvath J. C. (2000): Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol., 16, 1-15.
370. Sinkovics J. G. and Horvath J. C. (2000): Vaccination against human cancers. Int. J. Oncol., 16, 81-96.
371. Sinkovics J. G. and Horvath J. C. (2005): Human natural killer cells: a comprehensive review. Int. J. Oncol., 27, 5-47.
372. Sinkovics J. G. and Horvath J. C. (2006): Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int. J. Oncol., 29, 765-777.
373. Sinkovics J. G. and Horvath J. C. (2006): The molecular biology and immunology of glioblastoma multiforme (GMF) with the presentation of an immunotherapy protocol for a clinical trial. Acta Microbiol. Immunol. Hung., 53, 367-429.
374. Sinkovics J. G. and Howe C. D. (1969): Superinfection of tumors with viruses. Experientia, 25, 733-734.
375. Sinkovics J. G., Kay H. D. and Thota H. (1976): Evaluation of chemoimmunotherapy regimens by in vitro lymphocyte cytotoxicity directed to cultured human tumor cells. Bibl. Haematol., 43, 281-284.
376. Sinkovics J. G., Papadopoulos N. E. and Plager C. (1982): Viral oncolysates for the immunotherapy of human tumors. In Yohn D. S. and Blakeslee J. R. (eds.): Advances in Comparative Leukemia Research. Elsevier, North Holland, 613-615.
377. Sinkovics J. G., Plager C. and McMurtrey M. J. (1978): Chemoimmunotherapy basic principles and clinical examples. In Moore M. (ed.): Proceedings 12th International Cancer Congress Plenary Lectures. Basis for Cancer Therapy, VI, 121-129.
378. Sinkovics J. G., Plager C., McMurtrey M., Papadopoulos N. E., Waldinger R., Combs S., Romero J. and Romsdahl M. M. (1980): Adjuvant chemoimmunotherapy for malignant melanoma. In Crispen R. G. (ed.): Neoplasm Immunity: Experimental and Clinical. Elsevier, North Holland, 481-519.
379. Sinkovics J. G., Plager C. and Romero J. (1977): Immunology and immunotherapy of patients with sarcomas. In Crispen R. G. (ed.): Neoplasm Immunity: Solid Tumor Therapy. Franklin Institute Press, Philadelphia, 211-219.
380. Smith E. M., Dion L. D. and Blalock J. E. (1985): Opiate receptor mediated effects of endorphin-like peptides. Prog. Clin. Biol. Res., 192, 250-264.
381. Southam C. M. and Moore A. E. (1952): Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer, 5, 1025-1034.
382. Spaner D. E., Astsaturov I., Vogel T., Petrella T., Elias I., Burdett-Radoux S., Verma S., Hamilton P. and Berinstein N. L. (2006): Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer, 106, 890-899.
383. Springer C. J., Dowell R., Burke P. J., Hadley E., Davis D. H., Blakey D. C., Melton R. G. and Niculescu-Duvaz I. (1995): Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem., 38, 5051-5065.
384. Stanford M. M., Barrett J. W., Nazarian S. H., Werden S. and McFadden G. (2007): Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J. Virol., 81, 1251-1260.
385. Stanford M. M. and McFadden G. (2007): Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin. Biol. Ther., 7, 1415-1425.
386. Stasakova J., Ferko B., Kittel C., Sereinig S., Romaniova J., Katinger H. and Egorov A. (2005): Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukin 1beta and 18. J. Gen. Virol., 86, 185-195.
387. Steiner H. H., Bonsanto M., Beckhove P., Brysch M., Geletneky K., Ahmadi R., Schuele-Freyer R., Kremer P., Ranaie G., Matejic D., Bauer H., Kiessling M., Kunze S., Schirrmacher V. and Herold-Mende C. (2004): Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol., 22, 4240-4243.
388. Steineur M. P., Grosjean I., Bella C. and Kaiserlian D. (1998): Langerhans cells are susceptible to measles virus infection and actively suppress T cell proliferation. Eur. J. Dermatol., 8, 413-420.
389. Stephenson K. B., Bridle B., Lun X., Davies E. J., Wan Y., Ashkar A., Forsyth P. A. and Lichty B. D. (2007): VSV expressing IL-15 as a potential immunostimulatory oncolytic virus. In The 4th International Conference on Oncolytic viruses as Cancer Therapeutics. Mayo Clinic College of Medicine, Rochester, USA. Abstract Book, Poster 20.
390. Sterman D. H., Gillespie C. T., Carroll R. G., Coughlin C. M., Lord E. M., Sun J., Hass A., Recio A., Kaiser L. R., Coukos G., June C. H., Albelda S. M. and Vonderheide R. H. (2006): Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat. Clin. Pract. Oncol., 3, 633-639.
391. Steward M., Vipond I. B., Millar N. S. and Emmerson P. T. (1993): RNA editing in Newcastle disease virus. J. Gen. Virol.,74, 2539-2547.
392. Stief A. E. and McCart J. A. (2008): Oncolytic virotherapy for multiple myeloma. Expert Opin. Biol. Ther., 8, 463-473.
393. Stoeckel J. and Hay J. G. (2006): Drug evaluation: Reolysin - wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther., 8, 249-260.
394. Stolarek R., Gomez-Manzano C., Jiang H., Suttle G., Lemoine M. G. and Fueyo J. (2004): Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther., 11, 713-720.
395. Strong J. E., Coffey M. C., Tang D., Sabinin P. and Lee P. W. (1998): The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J., 17, 3351-3362.
396. Su Z. Z., Luo Z. Y., Guo L. P., Li J. Z. and Liu Y. L. (1988): Inhibitory effect of parvovirus H-1 on cultured human tumour cells or transformed cells. Sci. Sin., 31, 69-80.
397. Syverton J. T. and Berry G. P. (1947): The superinfection of the rabbit papilloma (Shope) by extraneous viruses. J. Exp. Med., 86, 131-146.
398. Syverton J. T. and McLaren L. C. (1957): Stable and pure line cell strains derivation and comparative viral susceptibility. 1957. Texas Rep. Biol. Med., 15, 129-139.
399. Szeberényi J., Fábián Z., Törõcsik B., Kiss K. and Csatary L. K. (2003): Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am. J. Ther., 10, 282-288
400. Sziegoleit A., Fussle R. and Rott R. (1978): Alteration of the erythrocyte membrane during Newcastle disease virus-induced hemolysis. Med. Microbiol. Immunol., 165, 101-109.
401. Szöllösi J., Ember I., Trón L. and Kertai P. (1982): A follow-up study of the progression of spontaneous regression of leukemia in mouse strains. Cytometry, 3, 110-115.
402. Taddeo B. and Roizman B. (2006): The virion host shut-off protein (UL41) of herpes simplex virus 1 is an endoribonuclease with a substrate specificity similar to that of RNase A. J. Virol., 80, 9341-9345.
403. Tai C. K. and Kasahara N. (2008): Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci., 13, 3083-3095.
404. Takács M., Balog K., Tóth G., Balogh Z., Szomor K. N., Brojnás J., Rusvai E., Minárovits J. and Berencsi G. (2003): TT virus in Hungary: sequence heterogeneity and mixed infections. FEMS Immunol. Med. Microbiol., 35, 153-157.
405. Takagi M., Ishikawa K., Nagai H., Sasaki T., Gotoh K. and Koyama H. (1996): Detection of contamination of vaccine with the reticuloendotheliosis virus by reverse transcriptase polymerase chain reaction (RT-PCR). Virus Res., 40, 113-121.
406. Takahashi Y., Harashima N., Kajigaya S., Yokoyama H., Cherkasova E., McCoy P., Hanada K., Mena O., Kurlander R., Abdul T., Srinivasan R., Lundquist A., Malinzak E., Geller N., Lerman M. I. and Childs R. W. (2008): Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J. Clin. Invest., 118, 1099-1109.
407. Takehara M. (1975): Polykaryocytosis induced by vesicular stomatitis virus infection in BHK-21 cells. Arch. Virol., 49, 297-306.
408. Taqi A. M., Abdurrahman M. B., Yakubu A. M. and Fleming A. F. (1981): Regression of Hodgkin's disease after measles. Lancet, 2, 1112.
409. Ten R. M., Blank V., Le Bail O., Kourilsky P. and Israel A. (1993): Two factors, IRF1 and KBF1/NK-kappa B, cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus. C. R. Acad. Sci., 316, 496-501.
410. Todo T. (2008): Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front. Biosci., 13, 2060-2064.
411. Todo T., Ebright M. I., Fong Y. and Rabkin S. D. (2002): Oncolytic herpes simplex virus (G207) therapy: from basic to clinical. In Maruta H. (ed.): Tumor-Suppressing Viruses, and Drugs Innovative Cancer Therapy Approaches. Academic Press, San Diego-San Francisco - New York, 45-75.
412. Toyoda T., Sakaguchi T., Hirota H., Gotoh B., Kuma K., Miyata T. and Nagai Y. (1989): Newcastle disease evolution. II. Lack of gene recombination in generating virulent and avirulent strains. Virology, 169, 273-282.
413. Tsuchiyama T., Kaneko S., Nakamoto Y., Sakai Y., Honda M., Mukaida N. and Kobayashi K. (2003): Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractan protein-1 against hepatocellular carcinoma. Cancer Gene Ther., 10, 260-269.
414. Tsuchiyama T., Nakamot Y., Sakai Y., Marukawa Y., Kitahara M., Mukaida N. and Kaneko S. (2007): Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J. Immunol., 178, 574-583.
415. Tsukuda K., Wiewrodt R., Molnar-Kimber K., Jovanovic V. P. and Amin K. M. (2002): An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res., 62, 3443-3447.
416. Tsuruta Y., Preboev L., Glasgow J. N., Rein D. T., Kawakami Y., Alvarez R. D., Rocconi R. P., Siegal G. P., Dent P., Fisher P. B. and Curiel D. T. (2007): A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma-1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin. Cancer Res., 13, 2777-2783.
417. Tzadok-David Y., Metzkin-Eizenberg M. and Zakay-Rones Z. (1995): The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. Cancer Res. Clin. Oncol., 121, 169-174.
418. Ulasov I. V., Rivera A. A., Nettelbeck D. M., Rivera L. B., Mathis J. M., Sonabend A. M., Tyler M., Wang M., Douglas J. T. and Lesniak M. S. (2007): An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int. J. Oncol., 31, 77-1185.
419. Ulasov I. V., Rivera A. A., Sonabend A. M., Rivera L. B., Wang M., Zhu Z. B. and Lesniak M. S. (2007): Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol. Ther., 6, 679-685.
420. Ulasov I. V., Zhu Z. B., Tyler M. A., Han Y., Rivera A. A., Khramtsov A., Curiel D. T. and Lesniak M. S. (2007): Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum. Gene Ther., 18, 589-602.
421. Ungerechts G., Springfeld C., Frenzke M. E., Lampe J., Johnston P. B., Parker W. B., Sorscher E. J. and Cattaneo R. (2007): Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res., 67, 10939-10947.
422. Unno Y., Shinio Y., Kondo F., Igarashi N., Wang G., Shimura R., Yamaguchi T., Asano T., Saisho H., Sekiya S. and Shirasawa H. (2005): Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin. Cancer Res., 11, 4553-4560.
423. Urwijitaroon Y., Barusrux S., Chunlertlith K., Mairiang P. and Yoshimura H. (2007): Torquetenovirus infection among northeastern Thai blood donors. Southeast Asian J. Trop. Med. Public Health, 38, 686-689.
424. Vähä-Koskela M. J., Haikkilä J. E. and Hinkkanen A. E. (2007): Oncolytic viruses in cancer therapy. Cancer Lett., 254, 178-216.
425. Varghese S., Rabkin S. D., Nielsen G. P., MacGarvey U., Liu R. and Martuza. R. L. (2007): Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res., 67, 9371-9379.
426. Veerapong J., Bickenbach K. A., Shao M. Y., Smith K. D., Posner M. C., Roizman B. and Weichselbaum R. R. (2007): Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res., 67, 8301-8306.
427. Vigil A., Park M.-S., Martinez O., Chua M., Xiao S., Cros J. F., Martinez-Sobrido L., Woo S. L. and García-Sastre A. (2007): Use of reverse genetics to improve the oncolytic properties of Newcastle disease virus. In The 4th International Conference on Oncolytic Viruses as Cancer Therapeutics. Mayo Clinic College of Medicine, Rochester, USA. Abstract Book, Poster 48.
428. Vilchez R. A. and Butel J. S. (2003): SV40 in human brain cancers and non-Hodgkin's lymphoma. Oncogene, 22, 5164-5172.
429. Vile R. G. (2006): Viral mediated cell fusion: viral fusion - the making or breaking of a tumor? Gene Ther., 13, 1127-1130.
430. Von Mehren M., Arien P., Tsang K. Y., Rogatko A., Meropol N., Cooper H. S., Davey M., McLaughlin S., Schlom J. and Weiner L. M. (2000): Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA)and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res., 6, 2219-2228.
431. Vorburger S. A., Pataer A., Swisher S. G. and Hunt K. K. (2004): Genetically targeted cancer therapy. Tumor destruction by PKR activation. Am. J. Pharmacogenomics, 4, 189-198.
432. Wagner S., Csatary C. M., Gosztonyi G., Koch H.C., Hartmann C., Petersa O., Hernaiz-Driever P., Theallier--Janko A., Zintl F., Langier A., Wolff J. E. and Csatary L. K. (2006): Combined treatment of pediatric high-grade glioma with oncolytic viral strain MTH-68/H and oral valproic acid. Acta Pathol. Microbiol. Immunol. Scand., 114, 731-743.
433. Wakayama M., Abei M., Kawashima R., Seo E., Fukuda K., Ugai H., Murata T., Tanaka N., Hyodo I., Hamada H. and Yokoyama K. K. (2007): E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin. Cancer Res., 13, 3043-3050.
434. Wakimoto H., Johnson P. R., Knipe D. M. and Chiocca E. A. (2003): Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther., 109, 83-990.
435. Wallack M. K. and Michaelides M. (1984): Serological response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surgery, 96, 791-800.
436. Wallack M. K., Sivanandham M., Balch C. M., Urist M. M., Bland K. I., Murray D., Robinson W. A., Flaherty L. E., Richards J. M. and Battolucci A. A. (1995): A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate active specific immunotherapy for patients with stage II melanoma. Cancer, 75, 34-42.
437. Wallack M. K., Sivanandham M., Balch C. M., Urist M. M., Bland K. I., Robinson W. A., Flaherty L., Richards J. M., Bartolucci A. A. and Rosen L. (1998): Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg., 187, 69-77.
438. Wallack M. K., Sivanandham M., Ditaranto K., Shaw P., Balch C. M., Urist M. M., Bland K. I., Murray D., Robinson W. A., Flaherty L., Richards J. M., Rosen L. and Bartolucci A. A. (1997): Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann. Surg., 226, 198-206.
439. Wang G., Barrett J. W., Stanford M., Werden S. J., Johnston J. B., Gao X., Sun M., Cheng J. Q. and McFadden G. (2006): Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA, 103, 4640-4645.
440. Wang Y., Xue S. A., Hallden G., Francis J., Yuan M., Griffin B. E. and Lemoine N. R. (2005): Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res., 65, 1523-1531.
441. Washburn B., Weigand M. A., Grosse-Wilde A., Janke M., Stahl H., Rieser E., Sprick M. R., Schirrmacher V. and Walczak H. (2003): TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J. Immunol., 170, 1814-1821.
442. Weil-Hillman G. and Zakay-Rones Z. (1985): Arrest of Daudi cell growth by influenza virus in vitro. Scan. Electron Microsc., Pt4, 1679-1686.
443. Wertz K., Buttner M., Mayr A. and Kaaden O. R. (1994): More than one component of the Newcastle disease virus particle is capable of interferon induction. Vet. Microbiol., 39, 299-311.
444. Westly H. J., Kleiss A. J., Kelley K. W., Wong P. K. and Yuen P.-H. (1986): Newcastle disease virus-infected splenocytes express the proopiomelanocortin gene. J. Exp. Med., 163, 1589-1594.
445. Westphal M. and Li C. H. (1984): Beta-endorphin: characterization of binding sites specific for the human glioblastoma SF126 cells. Proc. Natl. Acad. Sci. USA, 1, 2921-2923.
446. Wetzel K., Struyf S., Van Damme J., Kayser T., Vecchi A., Sozzani S., Rommelaere J., Cornelis J. J. and Dinsart C. (2007): MCP-3 (CCL7) delivered by
447. Wheelock E. F. and Dingle J. H. (1964): Observations on the repeated administration of viruses to patient with acute leukemia. N. Engl. J. Med., 271, 645-651.
448. White C. L., Twigger K. R., Vidal L., de Bono J. S., Coffey M., Heinemann L., Morgan R., Merrick A., Errington F., Vile R. G., Melcher A. A., Pandha H. S. and Harrington K. J. (2008): Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther., 15, 911-920.
449. Wilcox M. E., Yang W., Senger D., Rewcastle N. B., Morris D. G., Brasher P. M., Shi Z. Q., Johnston R. N., Nishikawa S., Lee P. W. and Forsyth P. A. (2001): Reovirus as an oncolytic agent against experimental human malignant glioma. J. Natl. Cancer Inst., 93, 903-912.
450. Wohlfahrt M. E., Beard B. C., Liebner A. and Kiem H. P. (2007): Capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res., 67, 8783-8790.
451. Wollmann G., Tattersall P. and van den Pol A. N. (2005): Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol., 79, 6005-6022.
452. Woo Y., Adusumilli P. S. and Fong Y. (2006): Advances in oncolytic viral therapy. Curr. Opin. Investig. Drugs, 7, 549-559.
453. Woodroofe G. M. and Fenner F. (1965): Viruses of the myxoma-fibroma subgroup of the poxviruses. I. Plaque production in cultured cells, plaque-reduction tests, and cross-protection tests in rabbits. Aust. J. Exp. Biol. Med., 43, 123-142.
454. Wu Y., Lun X., Zhou H., Wang L., Sun B., Bell J. C., Barrett J. W., McFadden G., Biegel J. A., Senger D. L. and Forsyth P. A. (2008): Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res., 14, 1218-1227.
455. Yaacov B., Elihaoo E., Lazar I., Ben-Shlomo M., Greenbaum I., Panet A. and Zakay-Rones Z. (2008): Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. (in press).
456. Yamada K., Moriyama H., Yasuda H., Hara K., Maniwa Y., Hamada H., Yokono K. and Nagata M. (2007): Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-kappaB activity. Hum. Gene Ther., 18, 389-400.
457. Yamini B., Yu X., Pytel P., Galanopoulos N., Rawlani V., Veerapong J., Bickenbach K. and Weichselbaum R. R. (2007): Adenovirally delivered tumor necrosis factor-α improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin. Cancer Res., 13, 6217-6223.
458. Yang S., Liu W., Cui H., Sun S. and Wang J. (2007): In vitro induction of apoptosis in tumor cells by inactivated NDV and IAV. Cancer Biother. Biopharm., 22, 200-205.
459. Yi K. H., Nechushtan H., Bowers W. J., Walker G. R., Zhang Y., Pham D. G., Podack E. R., Federoff H. J., Tolba K. A. and Rosenblatt J. D. (2007): Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res., 67, 10027-10037.
460. Yin D., Mufson R. A., Wang R. and Shi Y. (1999): Fas-mediated cell death promoted by opioids. Nature, 397, 218.
461. Yohn D. S., Hammon W. M., Atchison R. W. and Casto B. C. (1968): Oncolytic potentials of nonhuman viruses for human cancer. II. Effects of five viruses on heterotransplantable human tumors. J. Natl. Cancer Inst., 41, 523-529.
462. Yonemitsu Y., Ueda Y., Kinoh H. and Hasegawa M. (2008): Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Front Biosci., 13, 1892-1898.
463. York I. A., Roop C., Andrews D. W., Riddell S. R., Graham F. L. and Johnson D. (1994): A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell, 77, 525-535.
464. Yu W. and Fang H. (2007): Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets, 7, 141-148.
465. Yu Z. F., Lin M. F., Wang B. C., Lin X. J. and Lin X. H. (1981): Chemoimmunotherapy vs. chemotherapy in acute leukemia remission induction. Chin. Med. J., 94, 31-34.
466. Yusoff K., Millar N. S., Chambers P. and Emmerson P. T. (1987): Nucleotide sequence analysis of the L gene of Newcastle disease virus: homologies with Sendai and vesicular stomatitis virus. Nucleic Acids Res., 15, 3961-3976.
467. Yusoff K., Nesbit M., McCartney H., Meulemans G., Alexander D. J. Collins M. S, Emmerson P. T. and Samson A. C. (1989): Location of neutralizing epitopes on the fusion protein of Newcastle disease virus strain Beaudette C. J. Gen. Virol., 70, 3105-3109.
468. Zádori Z., Stefancsik R., Rauch T. and Kisary J. (1995): Analysis of the complete nucleotide sequences of goose and muscovy duck parvoviruses indicates common ancestral origin with adeno-associated virus 2. Virology, 212, 562-573.
469. Zeng J., Fournier P. and Schirrmacher V. (2004): High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int. J. Oncol., 25, 293-302.
470. Zhang F., Da R., Song W., Chen X., Zhang X., Li X. and Gu H. (2008): Pathogenic risk of endogenous retrovirus infection in immunodeficient hosts. Virus Res., 132, 237-241.
471. Zhang Q., Yu Y. A., Wang E., Chen N., Danner R. L., Munson P. J., Marincola F. M. and Szalay A. A. (2007): Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res., 67, 10038-10046.
472. Zhao H. C., Zhang Q., Yang Y., Lu M. Q., Li H., Xu C. and Chen G. H. (2007): p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro. World J. Gastroenterol., 13, 683-691.
473. Zheng H., Ye L., Fang X., Li B., Wang Y., Xiang X., Kong L., Wang W., Zeng Y., Ye L., Wu Z., She Y. and Zhou X. (2007): Torque teno virus (Sanban isolate) ORF2 protein suppresses NFkappaB pathways via interaction with IkappaB kinase. J. Virol., 81, 11917-11924.
474. Zhou G. and Roizman B. (2002): Truncated forms of glycoprotein D of herpes simplex virus 1 capable of blocking apoptosis and of low-efficiency entry into cells form a heterodimer dependent on the presence of a cysteine located in the shared transmembrane domains. J. Virol., 76, 11469-11475.
475. Zhu Z. B., Makhija S. K., Lu B., Wang M., Wang S., Takayama K., Siegal G. P., Reynolds P. N. and Curiel D. T. (2006): Targeting mesothelioma using infectivity enhanced survivin-conditionally replicative adenoviruses. J. Thorac. Oncol., 1, 701-711.
476. Zhu Z. B., Mathis J. M., Makhija S. K., Lu B., Wang M., Ji S, Rivera A. A., Rosenthal E. L., Siegal G. P. and Curiel D. T. (2007): Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Int. J. Oncol., 31, 1213-1222.
477. Zorn U., Dallmann I., Große J., Kirchner H., Poliwoda H. and Atzpodien J. (1994): Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother., 9, 225-235.
478. Zundelevich A., Elad-Sfadia G., Haklai R. and Kloog A. (2007): Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol. Cancer Ther., 6, 1765-1773.
479. La Scola B., Desnues C., Pagnier I., Robert C., Barrassi L., Fournous G., Merchat M., Suzan-Monti M., Forterre P., Koonin E. and Raoult D. (2008): The virophage as a unique parasite of the giant mimivirus. Nature, 455, 100-104.